Dimenhydrinate
A combination of diphenhydramine and 8-chlorotheophylline used to prevent and treat nausea, vomiting, and dizziness from motion sickness and vertigo. The diphenhydramine component blocks histamine and muscarinic receptors involved in the vomiting reflex. It commonly causes drowsiness, which can be both a therapeutic benefit (for motion sickness) and a limiting side effect.
Molekularmasse
470,0000 g/mol
TPSA
81,80 Ų
Therapeutische Bereiche
Wirkmechanismus
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O
InChI
InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)
Molecular Formula
C24H28ClN5O3
HBD / HBA
1 / 5
Rotierbare Bindungen
6
Schwere Atome
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A combination of diphenhydramine and 8-chlorotheophylline used to prevent and treat nausea, vomiting, and dizziness from motion sickness and vertigo. The diphenhydramine component blocks histamine and muscarinic receptors involved in the vomiting reflex. It commonly causes drowsiness, which can be both a therapeutic benefit (for motion sickness) and a limiting side effect.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Dimenhydrinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200406. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10660. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dimenhydrinate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dimenhydrinate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dimenhydrinate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dimenhydrinate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dimenhydrinate"></drugfyi-drug>